# A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

> **NCT05528861** · PHASE2 · TERMINATED · sponsor: **Allakos Inc.** · enrollment: 127 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** Lirentelimab (AK002)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05528861
- **Lead sponsor:** Allakos Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-26
- **Primary completion:** 2023-12-27
- **Final completion:** 2024-04-18
- **Target enrollment:** 127 (ACTUAL)
- **Why stopped:** No longer pursuing development
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05528861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05528861, "A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05528861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*